ELIAS Animal Health is a medical biotechnology company focused on advancing a pipeline of immunotherapies, including adoptive cell therapy and oncolytic immunotherapy, for the treatment of cancer in pets. The adoptive cell therapy – ELIAS Cancer Immunotherapy (ECI®) – is the first USDA-licensed product available for the treatment of canine osteosarcoma. ECI® combines an autologous vaccine with cell therapy to target a patient’s unique cancer cells. This personalized approach can improve clinical outcomes and provide a better quality of life for canine patients. The company’s therapeutic pipeline offers the prospect of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated. Current and upcoming clinical studies are focused on combination therapeutic approaches with ECI® at several locations throughout the United States. Learn more at www.eliasanimalhealth.com.